Not for human consumption, veterinary use, or clinical administration. Sold exclusively to qualified laboratories and researchers for in-vitro study.
The CJC-1295 + Ipamorelin blend is one of the most recognised combinations in growth-hormone secretagogue research. CJC-1295 is a synthetic analogue of growth-hormone-releasing hormone (GHRH), designed to have an extended half-life compared with native GHRH. Ipamorelin is a selective growth-hormone-releasing peptide (GHRP) that acts through the ghrelin receptor. Together, they are used in research models examining how these two complementary pathways interact.
Research on CJC-1295 has investigated its capacity to sustain elevated GH-releasing activity in pre-clinical models, while Ipamorelin studies have focused on its selectivity — it appears to stimulate GH release with less impact on cortisol and prolactin than earlier-generation GHRPs. The combination is frequently used in protocols exploring GH secretion dynamics and pituitary receptor signalling.
This blend is used in laboratory settings where researchers study the additive or synergistic effects of GHRH and GHRP co-administration. Supplied as a single vial, it is a practical preparation for labs exploring endocrine signalling without preparing two separate peptides.
myPEPT supplies this GH-secretagogue blend at ≥ 99% purity per component, accompanied by a Certificate of Analysis from third-party testing, and ships it lyophilised across the EU in research-grade packaging.
What researchers should know: this blend is for laboratory research use only and is not approved for human use. It is not a medicinal product and makes no therapeutic claim. Researchers should follow all applicable institutional and regulatory guidelines when working with GH-related peptides.
For research use only. This product is intended exclusively for in-vitro research and laboratory applications. Not approved for human or animal consumption, medical treatment, or therapeutic use.

